Dr. Samuel Wu joins Mesentech's Board of Directors

Sam has been a healthcare venture capital investor since 2002. He is a founding partner at Acuris, which was recently launched by the MedImmune Ventures team out of AstraZeneca. From 2010–2016 he was the managing director of MedImmune Ventures' West Coast office. Prior to that principal at SV Life Sciences where he invested in biopharmaceutical, platform and medical device companies. Sam has been a board member of Applied Genetic Technologies Corp (NASDAQ:AGTC), Cerapedics, Hydra Biosciences, Ocular Therapeutix (NASDAQ:OCUL), and the California Life Sciences Institute. Prior to his VC career, he was an Engagement Manager with McKinsey and Company, leading teams of consultants in M&A, portfolio analysis and other strategic issues.

Sam holds a B.A. magna cum laude in Biochemistry from Harvard University, and an M.D. Ph.D. from Stanford University School of Medicine.